XLSZ Stock Overview
Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Xlife Sciences AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF31.70 |
| 52 Week High | CHF43.40 |
| 52 Week Low | CHF31.70 |
| Beta | 0.30 |
| 1 Month Change | -26.79% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -26.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| XLSZ | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -9.2% | 7.4% | 1.0% |
| 1Y | n/a | -42.0% | 3.0% |
Return vs Industry: Insufficient data to determine how XLSZ performed against the UK Life Sciences industry.
Return vs Market: Insufficient data to determine how XLSZ performed against the UK Market.
Price Volatility
| XLSZ volatility | |
|---|---|
| XLSZ Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: XLSZ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine XLSZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 17 | Oliver Baumann | www.xlifesciences.ch |
Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences sector. The company’s project consists of technology platforms that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also engages in developing mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases; researching, developing, and manufacturing chemical and active pharmaceutical ingredients for human and veterinary medicines; and early identification kidney diseases.
Xlife Sciences AG Fundamentals Summary
| XLSZ fundamental statistics | |
|---|---|
| Market cap | CHF191.06m |
| Earnings (TTM) | CHF14.88m |
| Revenue (TTM) | CHF988.44k |
12.8x
P/E Ratio193.3x
P/S RatioIs XLSZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XLSZ income statement (TTM) | |
|---|---|
| Revenue | CHF988.44k |
| Cost of Revenue | CHF539.42k |
| Gross Profit | CHF449.02k |
| Other Expenses | -CHF14.43m |
| Earnings | CHF14.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 19, 2024
| Earnings per share (EPS) | 2.61 |
| Gross Margin | 45.43% |
| Net Profit Margin | 1,505.34% |
| Debt/Equity Ratio | 15.5% |
How did XLSZ perform over the long term?
See historical performance and comparison